JC06 Rec'd PCT/PTO 03 OCT 2005

PTO/SB/21 (09-04)
Approved for use through 07/31/2008. OMB 0651-0031
Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no	o persons		lection of info	emation unless it displays a valid OMB control number.
		Application Number	10/539,	545
TRANSMITTAL		Filing Date	June 16, 2005	
FORM		First Named Inventor	Stefan Berg	
•		Art Unit	To Be I	Determined
(to be used for all correspondence after initial filing)		Examiner Name	To Be Determined	
Total Number of Pages In This Submission	6	Attorney Docket Number	100915-	-1 US
roal vanion of roger in the desirious.				
	ENCL	LOSURES (Check all	that apply,	After Allowance Communication to TC
Fee Transmittal Form Fee Attached		Orawing(s) Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC
Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application		Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Clocks	Address	CAppeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please Identify below): Form PTO SB/08a and Form PTO SB/08b, 6 References, Copy of International Search Report & International-Type Search Report for International Application No. PCT/SE2003/001957
Reply to Missing Parts under 37 CFR 1.52 or 1.53	URE C	OF APPLICANT, ATTO	RNEY. C	DR AGENT
Firm Name				
AstraZeneca Pharma Signature AstraZeneca Pharma	K	ordiod.		
Karen H. Kondrad		· · · · · · · · · · · · · · · · · · ·	Pos No	T
Date Sept. 29.	20	05	Reg. No.	38,212
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on				
the date shown below: Signature	• .		loc	
Typed or printed name Marie M. Gre	loch			Date Sept 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stefan Berg, et al.

Serial No.: 10/539,545 Group Art Unit: To Be Determined

Filing Date: June 16, 2005 Examiner: To Be Determined

For: Novel Compounds Having Selective Inhibiting Effect at GSK3

MAIL STOP PCT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed. The Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PRO Forms SB/08A and SA/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

	within three months of the filing date of the patent.
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the International Application.
\boxtimes	before the mailing date of a first Office Action on the merits.

	date o	the mailing date of a first Office Action on the merits, but before the mailing of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance 37 C.F.R. § 1.311, and accordingly is accompanied by:					
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);					
		or					
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or					
	<u> </u>	no fee is owed by the applicant(s).					
	In accordance with 37 C.F.R. § 1.129(a), the Information Disclosure Statement is being filed in connection with \square the first or \square second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p) is attached.						
	After the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement", and "Fees" below).						
\boxtimes	attach enclo Septe	Copies of the references (excluding the US Patent Documents) listed on the attached PTO Forms SB/08a and SB/08b, formerly known as PTO Form 1449, a enclosed including a copy of the International-Type Search Report dated September 10, 2003, and International Search Report dated April 20, 2004 for International Application No. PCT/SE2003/001957.					
	EXC	EPT THAT:					
		In view of the voluminous nature of reference, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith					
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the US Patent and Trademark Office in the patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.					
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.					

Staten	nent under 37 C.F.R. § 1.97(e)				
	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more that three months prior to the filing of the Information Disclosure Statement.				
Fees.					
\boxtimes	No fee is owed by the applicant(s).				
	The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.				
Metho	od of Payment of Fees				
	Attached is a check in the amount of \$ This form is submitted in duplicate.				
	Charge Deposit Account No. 26-0166 in the amount of \$180.00. This form is submitted in duplicate.				
\boxtimes	Please charge any deficiency or credit any overpayment of Deposit Account 26-0166.				
	No fee or Statement is required under 37 C.F.R. § 1.97(b).				
	Respectfully submitted,				
Dated	Karen H. Kondrad Registration No.: 38,212				

Address Associated with Customer Number: 22466